Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation

Open access

Abstract

Kv1.3 potassium channels regulate microglial functions and are overexpressed in neuroinflammatory diseases. Kv1.3 blockade may selectively inhibit pro-inflammatory microglia in neurological diseases but the molecular and cellular mechanisms regulated by Kv1.3 channels are poorly defined. We performed immunoblotting and flow cytometry to confirm Kv1.3 channel upregulation in lipopolysaccharide (LPS)-activated BV2 microglia and in brain mononuclear phagocytes freshly isolated from LPS-treated mice. Quantitative proteomics was performed on BV2 microglia treated with control, LPS, ShK-223 (highly selective Kv1.3 blocker), and LPS+ShK-223. Gene ontology (GO) analyses of Kv1.3-dependent LPS-regulated proteins were performed, and the most representative proteins and GO terms were validated. Effects of Kv1.3-blockade on LPS-activated BV2 microglia were studied in migration, focal adhesion formation, reactive oxygen species production, and phagocytosis assays. In vivo validation of protein changes and predicted molecular pathways were performed in a model of systemic LPS-induced neuroinflammation, employing antigen presentation and T cell proliferation assays. Informed by pathway analyses of proteomic data, additional mechanistic experiments were performed to identify early Kv1.3-dependent signaling and transcriptional events. LPS-upregulated cell surface Kv1.3 channels in BV2 microglia and in microglia and CNS-infiltrating macrophages isolated from LPS-treated mice. Of 144 proteins differentially regulated by LPS (of 3141 proteins), 21 proteins showed rectification by ShK-223. Enriched cellular processes included MHCI-mediated antigen presentation (TAP1, EHD1), cell motility, and focal adhesion formation. In vitro, ShK-223 decreased LPS-induced focal adhesion formation, reversed LPS-induced inhibition of migration, and inhibited LPS-induced upregulation of EHD1, a protein involved in MHCI trafficking. In vivo, intra-peritoneal ShK-223 inhibited LPS-induced MHCI expression by CD11b + CD45 low microglia without affecting MHCI expression or trafficking of CD11b + CD45 high macrophages. ShK-223 inhibited LPS-induced MHCI-restricted antigen presentation to ovalbumin-specific CD8 + T cells both in vitro and in vivo. Kv1.3 co-localized with the LPS receptor complex and regulated LPS-induced early serine (S727) STAT1 phosphorylation. We have unraveled novel molecular and functional roles for Kv1.3 channels in pro-inflammatory microglial activation, including a Kv1.3 channel-regulated pathway that facilitates MHCI expression and MHCI-dependent antigen presentation by microglia to CD8 + T cells. We also provide evidence for neuro-immunomodulation by systemically administered ShK peptides. Our results further strengthen the therapeutic candidacy of microglial Kv1.3 channels in neurologic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-017-0906-6

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 LPS-activated BV2 microglia upregulate Kv1.3 channels. a Immunofluorescence microscopic comparison of Kv1.3 protein expression (detected by Anti-Kv1.3 rabbit pAb 1:500) by unstimulated and LPS-activated (100 ng/mL × 24 h) BV2 microglia. b Western blot confirmation of LPS dose-dependent increase in Kv1.3 protein in BV2 whole-cell lysates (Anti-Kv1.3 pAb 1:1000). c Immunofluorescence microscopic comparison of cell surface Kv1.3 channels in unstimulated and LPS-activated BV2 cells using ShK-F6CA. d Flow cytometric comparison of ShK-F6CA-labeled cell surface Kv1.3 channels and microglial activation marker ICAM-1 in unstimulated and LPS-activated BV2 cells. e Assessment of microglial activation markers MHCII and CD69 in unstimulated and LPS-activated BV2 cells
Fig. 1 LPS-activated BV2 microglia upregulate Kv1.3 channels. a Immunofluorescence microscopic comparison of Kv1.3 protein expression (detected by Anti-Kv1.3 rabbit pAb 1:500) by unstimulated and LPS-activated (100 ng/mL × 24 h) BV2 microglia. b Western blot confirmation of LPS dose-dependent increase in Kv1.3 protein in BV2 whole-cell lysates (Anti-Kv1.3 pAb 1:1000). c Immunofluorescence microscopic comparison of cell surface Kv1.3 channels in unstimulated and LPS-activated BV2 cells using ShK-F6CA. d Flow cytometric comparison of ShK-F6CA-labeled cell surface Kv1.3 channels and microglial activation marker ICAM-1 in unstimulated and LPS-activated BV2 cells. e Assessment of microglial activation markers MHCII and CD69 in unstimulated and LPS-activated BV2 cellsCC BY · PubMed Central
Fig. 2 In vivo demonstration of Kv1.3 channel upregulation by microglia and brain-infiltrating macrophages in a mouse model of LPS-induced neuroinflammation. a LPS was administered to adult C57BL/6 mice by tail vein injection, and brain mononuclear cells were analyzed by flow cytometry (CD11b, CD45, ShK-F6CA, and ICAM-1). b Most cells were CD11b+CD45low microglia while small populations of brain-infiltrating macrophages CD11b+CD45high and CD11b- non-myeloid cells were observed. c–e Comparison of Kv1.3 channel and ICAM-1 expression in brain mononuclear cells isolated from control and LPS-treated mice in microglia (c), brain-infiltrating macrophages (d), and CD11b- subpopulations (e) (*p < 0.05, **p < 0.01, ***p < 0.005)
Fig. 2 In vivo demonstration of Kv1.3 channel upregulation by microglia and brain-infiltrating macrophages in a mouse model of LPS-induced neuroinflammation. a LPS was administered to adult C57BL/6 mice by tail vein injection, and brain mononuclear cells were analyzed by flow cytometry (CD11b, CD45, ShK-F6CA, and ICAM-1). b Most cells were CD11b+CD45low microglia while small populations of brain-infiltrating macrophages CD11b+CD45high and CD11b- non-myeloid cells were observed. c–e Comparison of Kv1.3 channel and ICAM-1 expression in brain mononuclear cells isolated from control and LPS-treated mice in microglia (c), brain-infiltrating macrophages (d), and CD11b- subpopulations (e) (*p < 0.05, **p < 0.01, ***p < 0.005)CC BY · PubMed Central
Fig. 3 Identification of novel Kv1.3 channel-dependent molecular mechanisms by microglial quantitative proteomics. BV2 microglia were exposed to PBS, LPS (100 ng/mL), ShK-223 (100 nM), or LPS+ShK-223 for 24 h (3 replicates/group) and whole-cell lysates were used for mass-spectrometric analysis. a Volcano-plot: Of 450 proteins differentially expressed across all 4 groups (black dots), 144 proteins were significantly up- or downregulated following LPS exposure (top-right and top-left quadrants; vertical dotted lines represent the upper and lower boundaries of 1.25-fold change threshold while the horizontal dotted line represents p value threshold of 0.05 comparing LPS vs. control groups). Among these, ShK-223 reversed the LPS effect in 21 proteins (highlighted in red). b LPS-upregulated proteins that were reversed by ShK-223 and c LPS-downregulated proteins reversed by ShK-223 are shown. Relative expression represents label-free quantitation data in each treatment condition normalized to the control PBS group. The dotted horizontal line represents the twofold change threshold as compared to the PBS group. d–f Circle plots representing results from GO analyses are shown (gray: protein/gene symbol, red: biological process, green: cellular component, purple: molecular function). Only significantly enriched GO terms (unadjusted p ≤ 0.05 based on enrichment score) are shown (*p < 0.05, **p < 0.01, ***p < 0.005). d GO analysis of 21 LPS-regulated Kv1.3-dependent proteins (n = 21, stringent p ≤ 0.05 threshold comparing LPS vs. LPS+ShK-223). e GO analysis of LPS-upregulated Kv1.3-dependent proteins (n = 26, p ≤ 0.10 threshold comparing LPS vs. LPS+ShK-223). f GO analysis of LPS-downregulated Kv1.3-dependent proteins (n = 40, p ≤ 0.10 threshold comparing LPS vs. LPS+ShK-223)
Fig. 3 Identification of novel Kv1.3 channel-dependent molecular mechanisms by microglial quantitative proteomics. BV2 microglia were exposed to PBS, LPS (100 ng/mL), ShK-223 (100 nM), or LPS+ShK-223 for 24 h (3 replicates/group) and whole-cell lysates were used for mass-spectrometric analysis. a Volcano-plot: Of 450 proteins differentially expressed across all 4 groups (black dots), 144 proteins were significantly up- or downregulated following LPS exposure (top-right and top-left quadrants; vertical dotted lines represent the upper and lower boundaries of 1.25-fold change threshold while the horizontal dotted line represents p value threshold of 0.05 comparing LPS vs. control groups). Among these, ShK-223 reversed the LPS effect in 21 proteins (highlighted in red). b LPS-upregulated proteins that were reversed by ShK-223 and c LPS-downregulated proteins reversed by ShK-223 are shown. Relative expression represents label-free quantitation data in each treatment condition normalized to the control PBS group. The dotted horizontal line represents the twofold change threshold as compared to the PBS group. d–f Circle plots representing results from GO analyses are shown (gray: protein/gene symbol, red: biological process, green: cellular component, purple: molecular function). Only significantly enriched GO terms (unadjusted p ≤ 0.05 based on enrichment score) are shown (*p < 0.05, **p < 0.01, ***p < 0.005). d GO analysis of 21 LPS-regulated Kv1.3-dependent proteins (n = 21, stringent p ≤ 0.05 threshold comparing LPS vs. LPS+ShK-223). e GO analysis of LPS-upregulated Kv1.3-dependent proteins (n = 26, p ≤ 0.10 threshold comparing LPS vs. LPS+ShK-223). f GO analysis of LPS-downregulated Kv1.3-dependent proteins (n = 40, p ≤ 0.10 threshold comparing LPS vs. LPS+ShK-223)CC BY · PubMed Central
Fig. 4 Kv1.3 channels regulate microglial taxis and formation of F-actin complexes induced by LPS. a In the gap closure assay of microglial taxis, BV2 cells were grown to near confluence followed by placement of a uniform scratch using a 200-μm pipette tip. Ability of microglia to close this gap was assessed by measuring the percentage of gap closure over a 24-h period. Paired (0 and 24 h) representative images from each treatment group are shown (a, left), and the comparison of percentage gap closure (over 24 h) is shown (a, right) (six replicates per condition). b BV2 microglial transmigration across a transwell membrane (8-μm pore diameter) after exposure to control, ShK-223, ShK-186, LPS or LPS+ShK-223, or ShK-186, towards serum-containing medium (10% fetal bovine serum). Following 24 h of transmigration, cells were detached from undersurface of the insert (0.25% Trypsin), and cells that successfully migrated across the membrane were counted on a hemocytometer (n = 3, independent experiments). c Comparison of F-actin containing focal adhesion complexes in BV2 microglia following exposure to control, ShK-223, LPS, or LPS+ShK-223. Fixed and permeabilized BV2 cells were labeled with phalloidin-rhodamine to detect F-actin (left: immunofluorescence images). The number of focal complexes were counted per cell at ×40 magnification (right) and compared (>25 cells counted per condition). d DCFDA assay of ROS production by brain mononuclear cells isolated from C57BL/6 mice treated with PBS, LPS, ShK-223, or LPS+ShK-223 IP for four consecutive days (n = 3, mice/group). Cells were loaded with DCFDA for 30 min and assayed for ROS activity by flow cytometry. e Flow cytometric phagocytosis assay of fluorescent (PE) microbeads by brain mononuclear cells isolated from C57B6/L mice treated with PBS, LPS, ShK-223, or LPS+ShK-223, n = 3/group). Dotted line: fluorescence of cells not exposed to beads; gray histogram: PBS-treated; black histogram: LPS-treated. The proportions of all phagocytic cells and highly phagocytic cells were compared across treatment groups (*p < 0.05, **p < 0.01, ***p < 0.005)
Fig. 4 Kv1.3 channels regulate microglial taxis and formation of F-actin complexes induced by LPS. a In the gap closure assay of microglial taxis, BV2 cells were grown to near confluence followed by placement of a uniform scratch using a 200-μm pipette tip. Ability of microglia to close this gap was assessed by measuring the percentage of gap closure over a 24-h period. Paired (0 and 24 h) representative images from each treatment group are shown (a, left), and the comparison of percentage gap closure (over 24 h) is shown (a, right) (six replicates per condition). b BV2 microglial transmigration across a transwell membrane (8-μm pore diameter) after exposure to control, ShK-223, ShK-186, LPS or LPS+ShK-223, or ShK-186, towards serum-containing medium (10% fetal bovine serum). Following 24 h of transmigration, cells were detached from undersurface of the insert (0.25% Trypsin), and cells that successfully migrated across the membrane were counted on a hemocytometer (n = 3, independent experiments). c Comparison of F-actin containing focal adhesion complexes in BV2 microglia following exposure to control, ShK-223, LPS, or LPS+ShK-223. Fixed and permeabilized BV2 cells were labeled with phalloidin-rhodamine to detect F-actin (left: immunofluorescence images). The number of focal complexes were counted per cell at ×40 magnification (right) and compared (>25 cells counted per condition). d DCFDA assay of ROS production by brain mononuclear cells isolated from C57BL/6 mice treated with PBS, LPS, ShK-223, or LPS+ShK-223 IP for four consecutive days (n = 3, mice/group). Cells were loaded with DCFDA for 30 min and assayed for ROS activity by flow cytometry. e Flow cytometric phagocytosis assay of fluorescent (PE) microbeads by brain mononuclear cells isolated from C57B6/L mice treated with PBS, LPS, ShK-223, or LPS+ShK-223, n = 3/group). Dotted line: fluorescence of cells not exposed to beads; gray histogram: PBS-treated; black histogram: LPS-treated. The proportions of all phagocytic cells and highly phagocytic cells were compared across treatment groups (*p < 0.05, **p < 0.01, ***p < 0.005)CC BY · PubMed Central
Fig. 5 Kv1.3 channels regulate TAP1, EHD1, GABPA, and IL1B expression in primary murine microglia. a Experimental plan for in vivo studies: adult C57BL/6 mice received four daily IP doses of PBS, ShK-223, LPS, or LPS+ShK-223, and brain mononuclear cells were isolated for flow cytometry from one hemisphere and qRT-PCR studies from the other hemisphere (n = 3, mice/group). b Results from flow cytometric studies measuring intracellular EHD1 protein expression in freshly isolated CNS MPs (gated first on live cells, followed by CD11b+ CD45low and CD11b+ CD45high populations). At least 10,000 live CNS MPs were counted per sample. Left: Example of flow cytometric histograms comparing EHD1 expression in CD11b+ CD45low microglia from one mouse from each treatment group. Right: Quantitative analysis of EHD1+ cells in CD11b+CD45low and CD11b+CD45high populations. c Results from pRT-PCR studies measuring mRNA expression of TAP1, EHD1, GABPA, and IL1B in CNS MPs. For these studies, all CNS MPs isolated from one hemisphere were used for RNA extraction in Trizol, followed by cDNA preparation followed by quantitative PCR. HPRT was used as the housekeeping gene. Data normalized to HPRT were then normalized to PBS-treated control samples (*p < 0.05, **p < 0.01, ***p < 0.005).
Fig. 5 Kv1.3 channels regulate TAP1, EHD1, GABPA, and IL1B expression in primary murine microglia. a Experimental plan for in vivo studies: adult C57BL/6 mice received four daily IP doses of PBS, ShK-223, LPS, or LPS+ShK-223, and brain mononuclear cells were isolated for flow cytometry from one hemisphere and qRT-PCR studies from the other hemisphere (n = 3, mice/group). b Results from flow cytometric studies measuring intracellular EHD1 protein expression in freshly isolated CNS MPs (gated first on live cells, followed by CD11b+ CD45low and CD11b+ CD45high populations). At least 10,000 live CNS MPs were counted per sample. Left: Example of flow cytometric histograms comparing EHD1 expression in CD11b+ CD45low microglia from one mouse from each treatment group. Right: Quantitative analysis of EHD1+ cells in CD11b+CD45low and CD11b+CD45high populations. c Results from pRT-PCR studies measuring mRNA expression of TAP1, EHD1, GABPA, and IL1B in CNS MPs. For these studies, all CNS MPs isolated from one hemisphere were used for RNA extraction in Trizol, followed by cDNA preparation followed by quantitative PCR. HPRT was used as the housekeeping gene. Data normalized to HPRT were then normalized to PBS-treated control samples (*p < 0.05, **p < 0.01, ***p < 0.005).CC BY · PubMed Central
Fig. 6 LPS-induced MHCI trafficking in microglia involves Kv1.3 channels. a Comparison of MHCI and MHCI-related protein expression in BV2 proteomic data. Normalized LFQ data (compared to control-treatment) is shown (three replicates/group). b Experimental plan for in vivo studies: Adult C57BL/6 mice received four daily IP doses of PBS, ShK-223, LPS, or LPS+ShK-223 and brain mononuclear cells were isolated for flow cytometry (pooled n = 9/group). c Comparison of MHCI (H2Kb) expression (median fluorescence intensity) in CD11b+ CD45low microglia. d Representative flow cytometry frequency histograms of MHCI expression in CD11b+ CD45low microglia. e Comparison of MHCI expression in CD11b+CD45high brain-infiltrating macrophages. f Comparison of the proportions of CD11b+CD45high CNS macrophages (among all CD11b+ cells) in the four treatment groups (*p < 0.05, **p < 0.01, ***p < 0.005)
Fig. 6 LPS-induced MHCI trafficking in microglia involves Kv1.3 channels. a Comparison of MHCI and MHCI-related protein expression in BV2 proteomic data. Normalized LFQ data (compared to control-treatment) is shown (three replicates/group). b Experimental plan for in vivo studies: Adult C57BL/6 mice received four daily IP doses of PBS, ShK-223, LPS, or LPS+ShK-223 and brain mononuclear cells were isolated for flow cytometry (pooled n = 9/group). c Comparison of MHCI (H2Kb) expression (median fluorescence intensity) in CD11b+ CD45low microglia. d Representative flow cytometry frequency histograms of MHCI expression in CD11b+ CD45low microglia. e Comparison of MHCI expression in CD11b+CD45high brain-infiltrating macrophages. f Comparison of the proportions of CD11b+CD45high CNS macrophages (among all CD11b+ cells) in the four treatment groups (*p < 0.05, **p < 0.01, ***p < 0.005)CC BY · PubMed Central
Fig. 7 Kv1.3 blockade inhibits LPS-induced MHCI-restricted antigen presentation to CD8 T cells. a Experimental plan for MHCI-restricted T cell proliferation studies: BV2 microglia were treated in vitro with PBS, ShK-223 (100 nM), LPS (100 ng/mL), or LPS+ShK-223 for 24 h (four replicates/group) and then loaded with 2 μg/mL Ova (257-264) peptide for 30 min at 37 °C. Washed microglia were co-cultured with CFSE-labeled splenic T cells from Ova (257-264)-specific OT-1 mice for 48 h (25,000 microglia:150,000 T cells/well). For in vivo experiments, adult wild-type mice were treated with four daily IP doses of saline, ShK-223, LPS, or LPS+ShK-223 (n = 6/group) and isolated brain mononuclear cells were used for in vitro T cell proliferation studies. After 48 h, CFSE dilution (leftward shift in CFSE staining) was assessed by flow cytometry as a measure of CD8+ T cell proliferation. b Comparison of proliferating CD8+ cells across various treatment groups from in vitro and in vivo studies. Right: Representative frequency histograms from in vivo experiments. No direct effects of LPS or Ova peptide on T cells were noted without the presence of microglia. c Flow cytometric detection of CD3+ CD11b− T cells in brain mononuclear cells after thorough cardiac perfusion. Mice were injected (IP, once daily for 4 days) with PBS, LPS, ShK-223, or LPS+ShK-223. Panel a shows the gating strategy. After forward and side-scatter gating for live mononuclear cell population, CD11b− CD3+ cells were gated and assessed for T cell markers (CD3, CD8) and activation/cytolytic marker CD95 (Fas). d Flow cytometric evidence for increased CD8+ T cell trafficking to the brain following LPS treatment. e Comparison of proportions of brain CD8+ and CD8− T cell populations across the 4 treatment groups. f Comparison of CD95 (Fas) expression in brain CD8+ and CD8− T cell populations across treatment groups (*p < 0.05, **p < 0.01, ***p < 0.005)
Fig. 7 Kv1.3 blockade inhibits LPS-induced MHCI-restricted antigen presentation to CD8 T cells. a Experimental plan for MHCI-restricted T cell proliferation studies: BV2 microglia were treated in vitro with PBS, ShK-223 (100 nM), LPS (100 ng/mL), or LPS+ShK-223 for 24 h (four replicates/group) and then loaded with 2 μg/mL Ova (257-264) peptide for 30 min at 37 °C. Washed microglia were co-cultured with CFSE-labeled splenic T cells from Ova (257-264)-specific OT-1 mice for 48 h (25,000 microglia:150,000 T cells/well). For in vivo experiments, adult wild-type mice were treated with four daily IP doses of saline, ShK-223, LPS, or LPS+ShK-223 (n = 6/group) and isolated brain mononuclear cells were used for in vitro T cell proliferation studies. After 48 h, CFSE dilution (leftward shift in CFSE staining) was assessed by flow cytometry as a measure of CD8+ T cell proliferation. b Comparison of proliferating CD8+ cells across various treatment groups from in vitro and in vivo studies. Right: Representative frequency histograms from in vivo experiments. No direct effects of LPS or Ova peptide on T cells were noted without the presence of microglia. c Flow cytometric detection of CD3+ CD11b− T cells in brain mononuclear cells after thorough cardiac perfusion. Mice were injected (IP, once daily for 4 days) with PBS, LPS, ShK-223, or LPS+ShK-223. Panel a shows the gating strategy. After forward and side-scatter gating for live mononuclear cell population, CD11b− CD3+ cells were gated and assessed for T cell markers (CD3, CD8) and activation/cytolytic marker CD95 (Fas). d Flow cytometric evidence for increased CD8+ T cell trafficking to the brain following LPS treatment. e Comparison of proportions of brain CD8+ and CD8− T cell populations across the 4 treatment groups. f Comparison of CD95 (Fas) expression in brain CD8+ and CD8− T cell populations across treatment groups (*p < 0.05, **p < 0.01, ***p < 0.005)CC BY · PubMed Central
Fig. 8 Identification of Kv1.3-regulated signaling mechanisms in LPS-induced microglial activation. a, b Canonical pathway analysis of 120 Kv1.3-dependent proteins identified in our proteomic dataset revealed highly represented signaling pathways, two of which are shown here (see Additional file 2: Table S5 for others). Members of this list of 120 proteins are marked with (red circle). Transcription factors are also highlighted (transparent red circle). Arrows indicate directionality of the interaction (upstream vs. downstream). a GABPA, a Kv1.3-dependent transcription factor that was downregulated by LPS, was placed upstream of several Kv1.3-regulated proteins. b MHCI proteins of relevance to our results (TAP1, Tapasin, and EHD1 proteins) were represented in a signaling network that suggested that STAT1 and IRF1 may serve as upstream regulators of these proteins. c Comparison of normalized protein expression of transcription factors identified in our proteomic dataset across treatment groups. d Quantitative RT-PCR data comparing IRF1, IRF7, and NFKB1 mRNA expression across treatment groups (paired t tests were used for these comparisons; six replicates/group). e Phospho-flow cytometric studies of serine (S727) and tyrosine (Y701) STAT1 phosphorylation in BV2 microglia (n = 5/treatment group) at 30-min and 3-h time points. f Immunofluorescence microscopy showing partial co-localization between Kv1.3 (green, detected by ShK-F6CA labeling) and CD14 (red) in LPS-activated BV2 microglia (*p < 0.05, **p < 0.01, ***p < 0.005)
Fig. 8 Identification of Kv1.3-regulated signaling mechanisms in LPS-induced microglial activation. a, b Canonical pathway analysis of 120 Kv1.3-dependent proteins identified in our proteomic dataset revealed highly represented signaling pathways, two of which are shown here (see Additional file 2: Table S5 for others). Members of this list of 120 proteins are marked with (red circle). Transcription factors are also highlighted (transparent red circle). Arrows indicate directionality of the interaction (upstream vs. downstream). a GABPA, a Kv1.3-dependent transcription factor that was downregulated by LPS, was placed upstream of several Kv1.3-regulated proteins. b MHCI proteins of relevance to our results (TAP1, Tapasin, and EHD1 proteins) were represented in a signaling network that suggested that STAT1 and IRF1 may serve as upstream regulators of these proteins. c Comparison of normalized protein expression of transcription factors identified in our proteomic dataset across treatment groups. d Quantitative RT-PCR data comparing IRF1, IRF7, and NFKB1 mRNA expression across treatment groups (paired t tests were used for these comparisons; six replicates/group). e Phospho-flow cytometric studies of serine (S727) and tyrosine (Y701) STAT1 phosphorylation in BV2 microglia (n = 5/treatment group) at 30-min and 3-h time points. f Immunofluorescence microscopy showing partial co-localization between Kv1.3 (green, detected by ShK-F6CA labeling) and CD14 (red) in LPS-activated BV2 microglia (*p < 0.05, **p < 0.01, ***p < 0.005)CC BY · PubMed Central
Fig. 9 Cartoon showing the proposed mechanism by which Kv1.3 channel function regulates LPS-induced EHD1 and TAP1 upregulation and MHC I trafficking an antigen presentation by microglia
Fig. 9 Cartoon showing the proposed mechanism by which Kv1.3 channel function regulates LPS-induced EHD1 and TAP1 upregulation and MHC I trafficking an antigen presentation by microgliaCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Research works printed but not linked: 2

  1. Nguyen HM, Grossinger EM, Horiuchi M, Davis KW, Jin LW, Maezawa I, Wulff H: Differential Kv1.3, KCa3.1, and Kir2.1 expression in “classically” and “alternatively” activated microglia. Glia 2016. · DOI · Paper page
  2. Seyfried NT, Dammer EB, Swarup V, Nandakumar D, Duong DM, Yin L, Deng Q, Nguyen T, Hales CM, Wingo T, et al. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer’s disease. Cell systems. 2016. · DOI · Paper page

Cited by

See all 76

Metadata

Authors
Rangaraju, S., Raza, S. A., Pennati, A., Deng, Q., Dammer, E. B., Duong, D., Pennington, M. W., Tansey, M. G., Lah, J. J., Betarbet, R., Seyfried, N. T., & Levey, A. I.
Affiliations
  • Emory University (US)
  • University of Wisconsin–Madison (US)
  • Peptides International (United States) (US)
Corresponding author
Rangaraju, Srikant
Venue
Journal of Neuroinflammation
Published
2017-06-26
Volume
14
Issue
1
Pages
128-128
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2712049910
Cited by
75
References
64
Citations by year
2026: 6 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 18 · 2021: 7 · 2020: 12 · 2019: 6 · 2018: 9 · 2017: 2
FWCI
3.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institute of Neurological Disorders and Stroke (K08-NS099474-01, P30-NS055077)
  • National Institute on Aging (P50-AG025688, 1U01AG046161-01)
  • Alzheimer's Association (AARG-16-443621)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
Kv1.3 potassium channel, microglial activation, lipopolysaccharide, neuroinflammation, antigen presentation, EHD1, focal adhesions, microglial migration, reactive oxygen species, phagocytosis, CD8+ T cell proliferation, macrophages
MeSH terms
Animals, Cell Line, Cells, Cultured, Dose-Response Relationship, Drug, Female, Lipopolysaccharides, Macrophages, Mice, Inbred C57BL, Microglia, Proteomics, Mice, Kv1.3 Potassium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. https://app.cochat.ai/papers/10.1186/s12974-017-0906-6
The paper
Rangaraju, S., Raza, S. A., Pennati, A., Deng, Q., Dammer, E. B., Duong, D., Pennington, M. W., Tansey, M. G., Lah, J. J., Betarbet, R., Seyfried, N. T., & Levey, A. I. (2017). A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-017-0906-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.